NasdaqCM:DNTHBiotechs
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple
How the CAPTIVATE GO decision fits into the Dianthus story
Dianthus Therapeutics (DNTH) reached an early GO decision in its pivotal Phase 3 CAPTIVATE trial for claseprubart in chronic inflammatory demyelinating polyneuropathy, after hitting a predefined responder threshold ahead of schedule.
An independent committee confirmed the interim analysis, allowing the company to keep the 300mg every 2 weeks subcutaneous dosing in Part A and move toward refining Part B, while also engaging regulators...